407 related articles for article (PubMed ID: 32837681)
21. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.
Danielson PB
Curr Drug Metab; 2002 Dec; 3(6):561-97. PubMed ID: 12369887
[TBL] [Abstract][Full Text] [Related]
22. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
Shimada T; Mernaugh RL; Guengerich FP
Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
[TBL] [Abstract][Full Text] [Related]
23. Prediction of drug metabolism: the case of cytochrome P450 2D6.
Vermeulen NP
Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
[TBL] [Abstract][Full Text] [Related]
24. Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs.
Toselli F; Dodd PR; Gillam EM
Drug Metab Rev; 2016 Aug; 48(3):379-404. PubMed ID: 27498925
[TBL] [Abstract][Full Text] [Related]
25. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury.
Shimizu Y; Sasaki T; Yonekawa E; Yamazaki H; Ogura R; Watanabe M; Hosaka T; Shizu R; Takeshita JI; Yoshinari K
J Toxicol Sci; 2021; 46(4):167-176. PubMed ID: 33814510
[TBL] [Abstract][Full Text] [Related]
26. [From the Viewpoint of Drug Metabolism Research].
Nakajima M
Yakugaku Zasshi; 2017; 137(6):697-705. PubMed ID: 28566576
[TBL] [Abstract][Full Text] [Related]
27. Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development.
Fukami T; Yokoi T; Nakajima M
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():405-425. PubMed ID: 34499522
[TBL] [Abstract][Full Text] [Related]
28. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
Masubuchi Y; Horie T
Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
[TBL] [Abstract][Full Text] [Related]
29. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
Rendic SP
Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
[TBL] [Abstract][Full Text] [Related]
30. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
Rendic SP; Peter Guengerich F
Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
32. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
Orhan H; Vermeulen NP
Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective.
Kumar S; Sharma R; Roychowdhury A
Curr Med Chem; 2012; 19(21):3605-21. PubMed ID: 22680629
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction.
Furge LL; Guengerich FP
Biochem Mol Biol Educ; 2006 Mar; 34(2):66-74. PubMed ID: 21638641
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 networks in chemical space.
Lee S; Kim D
Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
[TBL] [Abstract][Full Text] [Related]
36. New trends in cytochrome p450 research at the half-century mark.
Guengerich FP
J Biol Chem; 2013 Jun; 288(24):17063-4. PubMed ID: 23632015
[TBL] [Abstract][Full Text] [Related]
37. Chimeric mice with humanized liver.
Katoh M; Tateno C; Yoshizato K; Yokoi T
Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
[TBL] [Abstract][Full Text] [Related]
38. From electrochemistry to enzyme kinetics of cytochrome P450.
Shumyantseva VV; Kuzikov AV; Masamrekh RA; Bulko TV; Archakov AI
Biosens Bioelectron; 2018 Dec; 121():192-204. PubMed ID: 30218927
[TBL] [Abstract][Full Text] [Related]
39. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
40. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
Rendic S; Guengerich FP
Curr Drug Metab; 2020; 21(14):1127-1135. PubMed ID: 33292107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
